STOCK TITAN

Moleculin Biotech (MBRX) Financials

MBRX NASDAQ
FY2025 annual
Revenue $0 n/m YoY
Net Income -$33.6M n/m YoY
Free Cash Flow -$22.7M n/m YoY
Operating Cash Flow -$22.7M n/m YoY
Market Cap $8.4M as of Nov 19, 2026
Price / Sales n/m revenue is not positive, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 0.6x on $14.5M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MBRX SEC filings page.

Moleculin Biotech, Inc. (MBRX) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MBRX FY2025

Moleculin remains a development-stage business, with research spending and recurring cash outflows funded primarily by external financing.

In FY2025, the net loss of $33.6M exceeded the operating cash outflow of $22.7M, indicating that accounting charges and working-capital effects materially shaped the gap between reported earnings and cash use. With capital expenditures at $0, free cash flow essentially matched operating cash flow, so reinvestment spending was not the main source of cash consumption.

Short-term coverage improved from 1.0x in FY2024 to 1.4x in FY2025, but the business still had no operating revenue to replenish those resources. Its reported liquidity comparison was 4.7 months of the latest annual operating outflow, describing the balance relative to that past outflow rather than establishing a forecast.

Research and development was $15.9M versus $9.1M of selling, general and administrative expense in FY2025, making scientific development the larger recurring expense. A $27.3M financing inflow exceeded the year's $22.7M operating cash outflow, showing that external capital—not operations—supplied the cash increase.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Moleculin Biotech, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Altman Z-Score Distress
-15.92

Moleculin Biotech, Inc. scores -15.92, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $206.0M against total assets of $22.1M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
4/7

Moleculin Biotech, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Moleculin Biotech, Inc. reported a net loss of $33.6M while operations used $22.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$0
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Moleculin Biotech, Inc. generated $0 in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EBITDA
-$6.6M
YoYn/m
QoQn/m
5Y CAGRn/m

Moleculin Biotech, Inc.'s EBITDA was -$6.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$6.5M
YoYn/m
QoQn/m

Moleculin Biotech, Inc. reported a net loss of $6.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$7.3M
YoY+8.7%
QoQ+0.3%
5Y CAGR-37.3%
10Y CAGR+1.7%

Moleculin Biotech, Inc. held $7.3M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
1M

Moleculin Biotech, Inc. had 1M shares outstanding in Q3 2026.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-44.8%
QoQ+21.1pp

Moleculin Biotech, Inc.'s quarterly ROE was -44.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is up 21.1 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$4.5M
YoY+20.1%
QoQ-17.7%
5Y CAGR+1.8%

Moleculin Biotech, Inc. invested $4.5M in research and development in Q3 2026. This represents an increase of 20.1% from the same quarter a year earlier. Against the prior quarter it is down 17.7%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

MBRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MBRX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
R&D Expenses$4.5M+20.1%$5.5M+51.4%$5.4M+56.6%$5.1M+14.9%$3.7M-24.2%$3.6M-12.0%$3.4M-19.2%$4.5M-32.8%
SG&A Expenses$2.1M-1.5%$2.1M+0.6%$2.5M+0.4%$2.4M+11.6%$2.1M-1.2%$2.1M+1.3%$2.5M+3.5%$2.2M-4.3%
Operating Income-$6.6Mn/m-$7.6Mn/m-$7.9Mn/m-$7.5Mn/m-$5.9Mn/m-$5.7Mn/m-$5.9Mn/m-$6.6Mn/m
EBITDA-$6.6Mn/m-$7.6Mn/m-$7.9Mn/m-$7.5Mn/m-$5.9Mn/m-$5.7Mn/m-$5.9Mn/m-$6.6Mn/m
Interest ExpenseN/A$78KN/AN/AN/AN/AN/AN/A
Income Tax$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Net Income-$6.5Mn/m-$7.6Mn/m-$12.8Mn/m$15.6M-$25.4Mn/m-$17.8Mn/m-$5.9Mn/mN/A
EPS (Basic)-$9.59-$1.40n/m-$3.54N/A-$0.34-$28.68-$15.80$0.51

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Diluted), Diluted Shares (Avg).

MBRX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MBRX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$20.7M+1.9%$21.1M-2.3%$23.4M+11.2%$22.1M+30.7%$20.4M-13.0%$21.6M-15.6%$21.0M-31.9%$16.9M-55.7%
Current Assets$8.4M+6.7%$8.7M-3.9%$11.0M+17.4%$9.7M+86.5%$7.9M-32.1%$9.1M-33.9%$9.3M-50.7%$5.2M-80.2%
Cash & Equivalents$7.3M+8.7%$7.3M-3.9%$10.3M+33.7%$8.9M+107.5%$6.7M-28.7%$7.6M-30.3%$7.7M-54.1%$4.3M-81.8%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$6.2M-86.8%$9.5M-62.3%$8.2M+13.3%$7.1M+24.5%$47.3M+690.1%$25.2M+219.9%$7.2M-22.0%$5.7M-52.9%
Current Liabilities$6.1M+8.0%$9.3M+17.7%$8.0M+15.5%$6.9M+27.9%$5.7M+1.6%$7.9M+37.7%$6.9M+27.5%$5.4M-21.4%
Non-Current Liabilities$112K-99.7%$187K-98.9%$218K-33.1%$266K-25.7%$41.6M+10564.4%$17.3M+712.9%$326K-91.5%$358K-93.3%
Total Equity$14.5Mn/m$11.6Mn/m$15.2M+10.1%$15.0M+33.9%-$26.9M-254.6%-$3.6M-118.5%$13.8M-44.8%$11.2M-63.8%
Retained Earnings-$233.0Mn/m-$226.5Mn/m-$218.8Mn/m-$206.0Mn/m-$221.6Mn/m-$196.2Mn/m-$178.3Mn/m-$172.4Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

MBRX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MBRX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$9.0Mn/m-$6.7Mn/m-$6.1Mn/m-$5.4Mn/m-$7.2Mn/m-$5.6Mn/m-$4.6Mn/m-$5.1Mn/m
Depreciation & Amortization$8K-61.9%$8K-72.4%$8K-74.2%$9K-71.0%$21K-32.3%$29K-6.5%$31K-3.1%$31K-11.4%
Stock-Based Compensation$393K+29.7%$436K+4.6%$380K-21.6%N/A$303K-14.2%$417K-7.9%$485K-1.6%N/A
Capital ExpendituresN/AN/AN/A$0n/m$0n/m$0-100.0%$0n/m$0-100.0%
Free Cash FlowN/AN/AN/A-$5.4Mn/m-$7.2Mn/m-$5.6Mn/m-$4.6Mn/m-$5.1Mn/m
Investing Cash Flow$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Financing Cash Flow$9.0M+41.6%$3.6M-33.4%$7.6M-4.8%$7.5M+748600.0%$6.4M+36.8%$5.4Mn/m$8.0Mn/m$1K-100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

MBRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MBRX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-44.8%-65.9%-84.6%-41.8pp103.6%N/AN/A-42.8%-17.1ppN/A
Return on Assets-31.3%+93.5pp-36.2%+46.3pp-55.0%-26.9pp70.3%-124.8%-94.8pp-82.5%-59.0pp-28.1%-7.3ppN/A
Current Ratio1.370.0x0.94-0.2x1.380.0x1.41+0.4x1.39-0.7x1.15-1.2x1.35-2.2x0.97-2.9x
Liabilities-to-Equity0.430.820.540.0x0.470.0xN/AN/A0.52+0.2x0.51+0.1x
Asset Turnover0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Moleculin Biotech, Inc. MBRX FY2025 $0 -$33.6M N/A $8.4M —
CalciMedica, Inc. CALC FY2025 N/A -$29.6M N/A $8.1M —
Tempest Therapeutics, Inc. TPST FY2025 N/A -$26.3M N/A $6.1M —
Soligenix, Inc. SNGX FY2025 N/A -$11.1M N/A $5.6M —
MetaVia Inc. MTVA FY2025 N/A -$13.0M N/A $7.2M —
Longeveron Inc. LGVN FY2025 $1.2M -$22.7M N/A $6.1M 54/100

Frequently Asked Questions

Moleculin Biotech, Inc. (MBRX) reported $0 in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Moleculin Biotech, Inc. (MBRX) reported a net loss of $33.6M in fiscal year 2025.

Moleculin Biotech, Inc. (MBRX) had EBITDA of -$25.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Moleculin Biotech, Inc. (MBRX) has a return on equity of -223.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Moleculin Biotech, Inc. (MBRX) recorded an outflow of $22.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Moleculin Biotech, Inc. (MBRX) recorded an outflow of $22.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Moleculin Biotech, Inc. (MBRX) had $22.1M in total assets as of fiscal year 2025, including both current and long-term assets.

Moleculin Biotech, Inc. (MBRX) reported no capital expenditure during fiscal year 2025.

Moleculin Biotech, Inc. (MBRX) invested $15.9M in research and development during fiscal year 2025.

Moleculin Biotech, Inc. (MBRX) had 5M shares outstanding as of fiscal year 2025.

Moleculin Biotech, Inc. (MBRX) had a current ratio of 1.41 as of fiscal year 2025, which is considered adequate.

Moleculin Biotech, Inc. (MBRX) had a liabilities-to-equity ratio of 0.47 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Moleculin Biotech, Inc. (MBRX) had a return on assets of -151.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Moleculin Biotech, Inc. (MBRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $8.4M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Moleculin Biotech, Inc. (MBRX) has no price-to-sales ratio at the moment: revenue is not positive (trailing 12 months to September 30, 2026). The market capitalization is $8.4M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Moleculin Biotech, Inc. (MBRX) held $8.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $22.7M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Moleculin Biotech, Inc. (MBRX) has an Altman Z-Score of -15.92, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Moleculin Biotech, Inc. (MBRX) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Moleculin Biotech, Inc. (MBRX) reported a net loss of $33.6M while operations used $22.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top